Optimal Vancomycin AUC Target in Pediatric MRSA Bacteremia: A Bayesian-guided Approach

Area of Science:

• Pediatric Infectious Diseases
• Pharmacokinetics and Pharmacodynamics
• Antimicrobial Stewardship

Background:

• Optimal vancomycin exposure targets for pediatric methicillin-resistant Staphylococcus aureus (MRSA) bacteremia are not well-defined.
• Vancomycin area under the curve (AUC) is a key pharmacokinetic parameter for efficacy and toxicity.

Purpose of the Study:

• To determine the optimal vancomycin AUC target for pediatric MRSA bacteremia.
• To evaluate the relationship between vancomycin AUC and clinical outcomes in children.

Main Methods:

• Retrospective analysis of pediatric patients (3 months to 18 years) with MRSA bacteremia.
• Vancomycin AUC estimation using Bayesian software.
• Analysis of AUC24-48 and outcomes: persistent bacteremia, acute kidney injury (AKI), mortality, and recurrence.

Main Results:

• A threshold of 530 mg·h/L for AUC24-48 was identified as optimal for predicting persistent bacteremia and AKI.
• Higher AUC24-48 (>530 mg·h/L) was associated with increased rates of persistent bacteremia and AKI.
• No significant differences in 30-day mortality or recurrence were observed based on AUC24-48 levels.

Conclusions:

• An AUC24-48 of ≤530 mg·h/L is associated with reduced persistent bacteremia and AKI in pediatric MRSA bacteremia.
• This target appears safe regarding mortality and recurrence.
• Further research is needed to define lower AUC limits for optimizing vancomycin therapy.